Predictive and pathological specificity of accelerated Brain-PACE

Determine whether accelerated Brain-PACE predicts subsequent clinical decline and whether it is specific to Alzheimer’s disease-related pathology.

Background

Brain-PACE was associated with tau burden, cognitive impairment, and functional impairment in the ADNI mild cognitive impairment cohort. However, the analysis was cross-sectional with respect to these clinical and biomarker associations and was restricted to a single cohort, so it does not establish whether accelerated Brain-PACE is prognostic of future decline or specifically reflects Alzheimer’s disease pathology rather than broader pathological ageing.

Resolving this problem would require longitudinal evaluation in cognitively unimpaired individuals with preclinical amyloid or tau pathology, together with assessment of clinical progression and treatment response, to establish the clinical validity and disease specificity of the measure.

References

Additionally, the biomarker analysis was restricted to the ADNI MCI group, so observed associations with tau and clinical severity do not establish whether accelerated Brain-PACE predicts subsequent decline, or is specific to AD-related pathology.

— Brain-PACE: A Deep Siamese MRI Framework for Modelling Longitudinal Brain Acceleration  (2609.11378 - Maddox et al., 10 Sep 2026) in Discussion, paragraph beginning “Future work should evaluate more diverse datasets”

Longitudinal analysis of tau PET is therefore required alongside Brain-PACE to determine if changes are in parallel with observed accumulation and spatial spread of pathology over time.

— Brain-PACE: A Deep Siamese MRI Framework for Modelling Longitudinal Brain Acceleration  (2609.11378 - Maddox et al., 10 Sep 2026) in Discussion, paragraph beginning “The association between Brain-PACE and regional tau burden”